Skip to main content

Advertisement

SpringerLink
Log in

Pain management in gout

  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Gout is currently the most common form of inflammatory arthritis in men. The overall incidence of gout has increased rapidly in the past 20 years. Clinicians in all fields are likely to experience a patient with acute gout in their career. Uncontrolled gout and hyperuricemia can lead to joint destruction and significant morbidity. Fortunately, these diseases can be readily treated and long-term sequelae can be prevented. Recent advances in understanding the role of the innate immune system in acute gout have provided new treatment options. This article addresses the epidemiology, inflammatory pathophysiology, pain management techniques (including recent advances), and treatment of the underlying disease itself.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Howe S, Edwards NL: Controlling hyperuricemia and gout in cardiac transplant recipients. J Musculoskelet Med 1995, 12:15–24.

    Google Scholar 

  2. Agudelo C, Wise C: Crystal-associated arthritis in the elderly. Rheum Dis Clin North Am 2000, 26:527–546.

    Article  PubMed  CAS  Google Scholar 

  3. Lawrence RC, Helmick CG, Arnett FC, et al.: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998, 41:778–799.

    Article  PubMed  CAS  Google Scholar 

  4. Choi HK, Ford ES: Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007, 120:442–447.

    Article  PubMed  Google Scholar 

  5. Choi HK, Churan G: Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. Brit Med J 2008, 336:309–312.

    Article  PubMed  Google Scholar 

  6. Popp JD, Bidgood WD, Edwards NL: Magnetic resonance imaging of tophaceous gout in the hands and wrists. Semin Arthritis Rheum 1996, 25:282–289.

    Article  PubMed  CAS  Google Scholar 

  7. Perez-Ruiz F, Martin I, Canteli B: Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 2007, 34:1888–1893.

    PubMed  Google Scholar 

  8. Jaramillo M, Godbout M, Naccache PH, et al.: Signaling events involved in macrophage chemokine expression in response to monosodium urate crystals. J Biol Chem 2004, 279:52797–52805.

    Article  PubMed  CAS  Google Scholar 

  9. Liu-Bryan R, Scott P, Sydlaske A, et al.: Innate immunity conferred by toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005, 52:2936–2946.

    Article  PubMed  CAS  Google Scholar 

  10. Maccagno A, Di Giorgio E, Romanowicz A: Effectiveness of etodolac (’Lodine’) compared with naproxen in patients with acute gout. Curr Med Res Opin 1991, 12:423–429.

    PubMed  CAS  Google Scholar 

  11. Shrestha M, Morgan DL, Moreden JM, et al.: Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995, 26:682–686.

    Article  PubMed  CAS  Google Scholar 

  12. Willburger RE, Mysler E, Derbot J, et al.: Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatol (Oxford) 2007, 46:1126–1132.

    Article  CAS  Google Scholar 

  13. Navarra S, Rubin BR, Yu Q, et al.: Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout. Curr Med Res Opin 2007, 23:1685–1691.

    Article  PubMed  CAS  Google Scholar 

  14. Schlesinger N: Management of acute and chronic gouty arthritis. Drugs 2004, 64:2399–2416.

    Article  PubMed  CAS  Google Scholar 

  15. Wallace SL: Colchicine analogs in the treatment of acute gout. Arthritis Rheum 1959, 2:389–394.

    Article  PubMed  CAS  Google Scholar 

  16. Ahern MJ, Reid C, Gordon TP: Does colchicine work? Results of the first controlled study in gout. Aust N Z J Med 1987, 17:301–304.

    PubMed  CAS  Google Scholar 

  17. Zhang W, Doherty M, Bardin T, et al.: EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Study Committee for Interventional Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312–1324.

    Article  PubMed  CAS  Google Scholar 

  18. Kuncl RW, Duncan G, Watson D, et al.: Colchicine myopathy and neuropathy. N Eng J Med 1987, 316:1562–1568.

    Article  CAS  Google Scholar 

  19. Siegal LB, Alloway JA, Nashel DJ: Comparison of adrenocorticotropic hormone and triamcinolone acetate in the treatment of acute gouty arthritis. J Rheumatol 1994, 21:1325–1337.

    Google Scholar 

  20. Getting SJ, Christian HC, Flower RJ, Perretti M: Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002, 46:2765–2775.

    Article  PubMed  CAS  Google Scholar 

  21. Hoffman HM, Firestein GS: Anakinra for the treatment of neonatal-onset multisystem inflammatory diseases. Nat Clin Pract Rheumatol 2006, 2:646–647.

    Article  PubMed  Google Scholar 

  22. So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.

    Article  PubMed  CAS  Google Scholar 

  23. Borstad GC, Bryant LR, Abel MP, et al.: Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004, 31:2429–2439.

    PubMed  CAS  Google Scholar 

  24. Hahn P, Edwards NL: Management of hyperuricemia. In Arthritis and Allied Conditions, 15th edn. Edited by Koopman WJ. Baltimore: Williams and Wilkins; 2004.

    Google Scholar 

  25. Scott JT: Comparison of allopurinol and probenecid. Ann Rheum Dis 1966, 25:623–626.

    PubMed  CAS  Google Scholar 

  26. Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47–56.

    Article  PubMed  CAS  Google Scholar 

  27. Perez-Ruiz FCM, Calabozo M, Fernandez-Lopez MJ, et al.: Treatment of chronic gout in patients with renal function impairment. An open, randomized, actively controlled study. J Clin Rheumatol 1999; 5:49–55.

    Article  CAS  PubMed  Google Scholar 

  28. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, et al.: Relationship between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis, 2001, 60:981–983.

    Article  PubMed  CAS  Google Scholar 

  29. The Gout & Uric Acid Education Society. Available at http://www.gouteducation.org. Accessed June 2008.

Download references

Author information

Authors and Affiliations

  1. 1600 SW Archer Road, Gainesville, FL, 32610, USA

    N. Lawrence Edwards

Authors
  1. Brian S. Kirby
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joan C. McTigue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Lawrence Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Lawrence Edwards.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kirby, B.S., McTigue, J.C. & Edwards, N.L. Pain management in gout. Current Science Inc 12, 418–422 (2008). https://doi.org/10.1007/s11916-008-0071-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11916-008-0071-9

Keywords

Search

Navigation